No Data
No Data
FDA Approves Pfizer's Second Hemophilia Drug With Six Months
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely
Sangamo Therapeutics Analyst Ratings
H.C. Wainwright Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $5
Earnings Update: Here's Why Analysts Just Lifted Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Price Target To US$3.80
No Data
No Data
WillLaw : Hope so, 41k shares here